Daiichi Sankyo Company, Limited

Pieris Pharmaceuticals Gmbh

Mamoru Otoyo

Ryuji Hashimoto

Tohru Takahashi

Andrea Allersdorfer

Christine Rothe

Marlon Hinner

Alexander Wiedenmann

Gabriele Matschiner

Rachida Siham Bel Aiba

Bradley Lunde

Kazufumi Kubota

Sakiko Takahashi

Mitsuhiro Makino

Nobuo Machinaga

Masakazu Tamura

Jun Chiba

Ryotaku Inoue

The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.

Proteins specific for calcitonin gene-related peptide

To provide a method for screening using cultured cells, intended to find a compound which increases the amount of sphingosine-1-phosphate or dihydrosphingosine-1-phosphate by SPL inhibitory activity rapidly, simply and highly sensitively. Provided are: a rapid and simple measurement method employing a scintillation proximity assay (SPA); a method with greatly improved detection sensitivity to the activity of a compound by controlling the concentration of the vitamin Bgroup in a culture medium to be used in assaying; and others.

Method for screening for S1P lyase inhibitors using cultured cells

To provide a novel compound that has S1P lyase inhibitory ability and induces a reduction in the number of lymphocytes, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound or pharmaceutically acceptable salt thereof as an active ingredient. A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof.

Phosphoric acid ester derivatives

Growing community of inventors

Tokyo, Japan

Mamoru Otoyo